Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 9;19(1):793.
doi: 10.1186/s12879-019-4415-3.

HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia

Ernesto Martínez Buitrago  1   2 , José Millán Oñate  3   4 , José Fernando García-Goez  3   5   6 , Jorge Álvarez  3   7 , William Lenis  3   8 , Luz Marina Sañudo  3 , Luisa Consuelo Rubiano  3   9
Affiliations

HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia

Ernesto Martínez Buitrago et al. BMC Infect Dis. .

Abstract

Background: The HLA-B*57:01 allele is associated with a hypersensitivity reaction to abacavir. Due to the lack of knowledge of HLA-B*57:01 prevalence in Colombia, routine screening is not performed and is not recommended by the national guidelines. We aimed to determine the prevalence of HLA-B*57:01 in HIV population from Colombia.

Methods: This cross-sectional study included naïve HIV-infected adults from 13 cities of the country. The presence of HLA-B*57:01 was determined by using SSP-PCR in blood samples. Prevalence rates were stratified by sex, race, and region of origin.

Results: HLA-B*57:01 allele prevalence in Colombian HIV-infected individuals was 2.7%. When stratifying for the race, the prevalence was 4% for whites, 2.6% for other race (mainly mestizo), and 1.9% for Afro-Colombians. The prevalence varied from 0% up to 11.4% depending on the department of origin. The highest prevalence rates were found in Caldas (11.4%), Antioquia (5%), Risaralda (4.8%), and Valle del Cauca (4.3%). When distributed by country zones, the central, with a racial predominance of Caucasians and mestizos, was the highest (6.0%, 0R = 4.1, CI 1.2-12.8, p = 0,016).

Conclusions: The overall prevalence of HLA-B*57:01 in Colombia was lower than the reported rates for other Latin American countries such as Brazil, Costa Rica, and Argentina, but similar in comparison to Chile and Mexico. The diversity in the racial and ethnic heritage shown in our data supports the recommendation to implement routine screening for the HLA-B*57:01 allele before initiation of abacavir-containing antiretroviral therapy in the Colombian HIV management guidelines.

Keywords: Abacavir; Antiretroviral therapy; HIV infection; HLA-B*57:01; Hypersensitivity; Pharmacogenetics. Cross-sectional study.

PubMed Disclaimer

Conflict of interest statement

EMB reports research grants from ViiV Healthcare/GSK, financial support for REVIVA foundation and VIHCOL Group (Grupo Colombiano de VIH) from GSK, MSD and Stendhal, and personal fees for presentations and advisory board meetings from GSK, MSD and Stendhal and presentations from Janssen Pharmaceuticals. JMO reports grants from ViiV Healthcare/GlaxoSmithKline, and personal fees from Merck Sharp & Dohme Colombia. JFO reports personal fees from Merck Sharp and Dohme Colombia. JA reports grants from ViiV Healthcare/GlaxoSmithKline and grants and personal fees from Merck Sharp & Dohme Colombia SAS. WL reports grants from ViiV Healthcare/GlaxoSmithKline, personal fees from Janssen Cilag SA, and Merck Sharp & Dohme Colombia; LR reports grants from ViiV Healthcare/GSK and Merck Sharp & Dohme Colombia. LMS declares no conflicts of interest.

Figures

Fig. 1
Fig. 1
Prevalence of HLA-B*5701 Carriers In Naïve HIV-1 Infected Individuals in Colombia, by Geografic Zone (lighter color) and Department of Origin (darker color)
See this image and copyright information in PMC

References

    1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services. (Updated 25 October 2018). https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. (2018).
    1. European AIDS Clinical Society. European AIDS Clinical Society Guidelines Version 9.1., Updated October 2018. http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html. (2018).
    1. Ministry of Health and Social Protection. Evidence-based clinical practice guidelines for HIV infection care of teenagers (13 years old and older) and adults. (2014).
    1. Mallal S, et al. HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase. Lancet. 2002;359:6. doi: 10.1016/S0140-6736(02)07873-X. - DOI - PubMed
    1. Hetherington S, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359:1121–1122. doi: 10.1016/S0140-6736(02)08158-8. - DOI - PubMed